DDInter702 DDInter782
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Etoposide {u} (Compound) resembles {v} (Compound) Podofilox
Etoposide {u} (Compound) treats {v} (Disease) urinary bladder cancer
Etoposide {u} (Compound) binds {v} (Gene) GSTT1
Etoposide {u} (Compound) upregulates {v} (Gene) COL11A1
Etoposide {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Etoposide {u} (Compound) downregulates {v} (Gene) AURKB
Etoposide {u} (Compound) causes {v} (Side Effect) Necrolysis epidermal
Etoposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Etoposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Etoposide (Compound) resembles Podofilox (Compound)
Etoposide (Compound) treats urinary bladder cancer (Disease)
Etoposide (Compound) binds GSTT1 (Gene)
Etoposide (Compound) upregulates COL11A1 (Gene)
Etoposide (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Etoposide (Compound) downregulates AURKB (Gene)
Etoposide (Compound) causes Necrolysis epidermal (Side Effect)
Etoposide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Etoposide may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Alefacept